Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 6/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | BMX | P51813 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23474657 | 0.95 | MAPT (0.33) | MAPTKDM4EL3MBTL1MAPK1NPSR1 | |
| SCHEMBL23474714 | 0.93 | MAPT (0.34) | MAPTKDM4EL3MBTL1MAPK1NPSR1 | |
| SCHEMBL22036685 | 0.89 | MAPT (0.35) | MAPTKDM4EL3MBTL1MAPK1NPSR1 | |
| SCHEMBL23474701 | 0.88 | KDM4E (0.32) | MAPTKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL23474648 | 0.87 | FLT3 (0.38) | MAPTKDM4EL3MBTL1MAPK1NPSR1 | |
| SCHEMBL19890654 | 0.87 | MAPT (0.33) | MAPTKDM4EL3MBTL1MAPK1NPSR1 | |
| SCHEMBL19890653 | 0.87 | MAPT (0.33) | MAPTKDM4EL3MBTL1MAPK1NPSR1 | |
| SCHEMBL21449288 | 0.84 | MAPT (0.33) | MAPTKDM4EL3MBTL1MAPK1NPSR1 | |
| SCHEMBL22036723 | 0.84 | MAPT (0.37) | MAPTKDM4EL3MBTL1MAPK1NPSR1 | |
| SCHEMBL17427663 | 0.84 | L3MBTL1 (0.39) | MAPTKDM4EL3MBTL1MAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787789-B2 | Compound for an organic electric element, an organic electric element using the same, and an electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-11787789-B2 | Compound for an organic electric element, an organic electric element using the same, and an electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-20210171510-A1 | COMPOUND FOR AN ORGANIC ELECTRIC ELEMENT, AN ORGANIC ELECTRIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787789-B2 | Compound for an organic electric element, an organic electric element using the same, and an electronic device thereof | PIEZO1, ORAI2, OCIAD1 | MAPT 3260/4885KDM4E 1227/4885L3MBTL1 792/4885 |
| US-20210171510-A1 | COMPOUND FOR AN ORGANIC ELECTRIC ELEMENT, AN ORGANIC ELECTRIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | PIEZO1, ORAI2, OCIAD1 | MAPT 3260/4885KDM4E 1227/4885L3MBTL1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.